News
Key Points GBM AGILE (NCT03970447) is an adaptive 'master protocol' study, in which different drug candidates can be tested for potential use in glioblastoma Study is designated phase II / III and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback